What is Nordic Nanovector ASA (NANOV.OL)?

Nordic Nanovector ASA (NANOV.OL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

Nordic Nanovector ASA (NANOV.OL)

Stock analysis · OSL · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

1.61

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Nordic Nanovector ASA (NANOV.OL) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Nov 18, 2021

EPS $-1.10 vs est. $-1.09

Missed by $0.01

Proprietary Signals

Signal snapshot temporarily unavailable.

About Nordic Nanovector ASA

Nordic Nanovector ASA, an Oslo, Norway-based biopharmaceutical firm, is dedicated to conceiving and commercializing treatments for hematological (blood) cancers. Its most advanced therapeutic, Betalutin—a CD37-targeting antibody-radionuclide conjugate—is currently undergoing Phase 2b clinical trials for individuals afflicted with non-Hodgkin lymphoma. The company's preclinical portfolio also features Alpha37, an anti-CD37 alpha-particle emitting radioimmunoconjugate being investigated for chronic lymphatic leukemia. Nordic Nanovector has forged collaboration agreements with several partners, such as the Paul Scherrer Institute, ArevaMed, LegoChem Bio, and Heidelberg Pharma. Additionally, it maintains a research partnership with the University of Pennsylvania to develop a CD37-targeting CAR-T cell strategy aimed at B-cell malignancies. Incorporated in 2009, the enterprise was formerly known as Nordic Nanovector AS before adopting its current name in 2014.